Clinical trial
Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V
NCT00097396 · DynPort Vaccine Company LLC, A GDIT Company, Industry · Completed
Key facts
| NCT number | NCT00097396 |
|---|---|
| Title | Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V |
| Official title | A Phase 1, Open-Label, Dose-Escalating Study to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant Plague Vaccine rF1V in Healthy Volunteers |
| Lead sponsor | DynPort Vaccine Company LLC, A GDIT Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pneumonic Plague, Preventive Therapy |
| Intervention type | Biological |
| Interventions | rF1V vaccine |
| Enrollment | 40 |
| Start date | Nov 1, 2004 |
| Primary completion | Jul 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Nov 24, 2004 |
| Last update posted | Jun 30, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: